Metastatic Hormone Refractory Prostate Cancer Market Share, Treatment, Analysis and Pipeline Review, H1 2016 by Radiant Insights
- Submitted by: marketresearchri
- Views: 64
- Category: Other
- Date Submitted: 07/26/2016 11:50 PM
- Pages: 5
- Report this Essay
Metastatic Hormone Refractory Prostate Cancer Market
Analysis and Pipeline Review, H1 2016 by Radiant Insights
Summary
Global Markets Direct's, 'Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate
Cancer - Pipeline Review, H1 2016', provides an overview of the Metastatic Hormone Refractory (Castration
Resistant, Androgen-Independent) Prostate Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Metastatic Hormone
Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The
report also covers the descriptive pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally, the report provides an overview of key
players involved in therapeutic development for Metastatic Hormone Refractory (Castration Resistant, AndrogenIndependent) Prostate Cancer and features dormant and discontinued projects.
View Full Report with TOC @ http://www.radiantinsights.com/research/metastatic-hormone-refractorycastration-resistant-androgen-independent-prostate-cancer-pipeline-review-h1-2016
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and
nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally, various dynamic tracking...
Analysis and Pipeline Review, H1 2016 by Radiant Insights
Summary
Global Markets Direct's, 'Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate
Cancer - Pipeline Review, H1 2016', provides an overview of the Metastatic Hormone Refractory (Castration
Resistant, Androgen-Independent) Prostate Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Metastatic Hormone
Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The
report also covers the descriptive pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally, the report provides an overview of key
players involved in therapeutic development for Metastatic Hormone Refractory (Castration Resistant, AndrogenIndependent) Prostate Cancer and features dormant and discontinued projects.
View Full Report with TOC @ http://www.radiantinsights.com/research/metastatic-hormone-refractorycastration-resistant-androgen-independent-prostate-cancer-pipeline-review-h1-2016
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and
nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally, various dynamic tracking...